ea0073oc8.2 | Oral Communications 8: Pituitary and Neuroendocrinology | ECE2021
Fleseriu Maria
, Biller Beverly
, Pivonello Rosario
, Akira Shimatsu
, Carla Scaroni
, Belaya Zhanna
, Vila Greisa
, Houde Ghislaine
, Walia Rama
, Izquierdo Miguel
, Roughton Michael
, Pedroncelli Alberto
, Newell-Price John
IntroductionOsilodrostat, a potent oral 11β-hydroxylase inhibitor, normalized mean urinary free cortisol (mUFC) in most patients with CD during the 48-week (W) core phase of a Phase III study (LINC3: NCT02180217). We present efficacy and safety results following an extension to LINC3.MethodsCD patients with mUFC > 1.5× upper limit of normal (ULN) received osilodrostat during the core. Patients b...